Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Schizophrenia Clear all
Completed Phase 3 Interventional

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

NCT00161018
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Deep Brain Stimulation for Psychosis

NCT06257056
View directory record Official record
Conditions
Treatment-Refractory Schizophrenia
Interventions
Abbott Laboratories Infinity™ implantable deep brain stimulation system
Device
Lead sponsor
Bradley Lega
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

NCT01963676
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
Interventions
tDCS, Sham stimulation
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 10, 2026, 4:14 PM EDT
Suspended Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia

NCT05259306
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Insightec Exablate Neuro MR-guided focused ultrasound transducer
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 3 Interventional

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bid, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Results available

Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia

NCT01595503
View directory record Official record
Conditions
Schizophrenia
Interventions
rTMS with fMRI-based targeting, rTMS with landmark-based targeting
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

NCT05299749
View directory record Official record
Conditions
Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
Interventions
stg-rt-fMRI-Neurofeeback, sham-rt-fMRI-Neurofeedback
Other
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Minocycline Augmentation to Clozapine

NCT02124811
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Minocycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 10, 2026, 4:14 PM EDT
Completed No phase listed Observational

Neural Biomarkers of Clozapine Response

NCT03076346
View directory record Official record
Conditions
Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 4 Interventional

Treating Drug-Resistant Childhood Schizophrenia

NCT00048828
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Dix Hills, New York • Glen Oaks, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 4 Interventional

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

NCT00169065
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
20 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 2Phase 3 Interventional

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCT03094429
View directory record Official record
Conditions
Refractory Schizophrenia
Interventions
NaBen®, Placebo
Drug · Other
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

NCT01569659
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 4 Interventional

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

NCT00169039
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Chlorpromazine
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
19 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Acetazolamide for Treatment Resistant Schizophrenia

NCT04887792
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
Vishwajit Nimgaonkar, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Results available

Treating Refractory Schizophrenia With rTMS

NCT02242578
View directory record Official record
Conditions
Schizophrenia
Interventions
1 Hz rTMS, 10 Hz rTMS
Device
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

NCT00158223
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Pimozide, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
New York, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 10, 2026, 4:14 PM EDT
Withdrawn Phase 2 Interventional

L-arginine Study for Persistent Symptoms of Schizophrenia

NCT04054973
View directory record Official record
Conditions
Schizo Affective Disorder, Schizophrenia
Interventions
L-arginine, Sapropterin Dihydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

NCT03485131
View directory record Official record
Conditions
Auditory Hallucination, Schizophrenia
Interventions
Transcranial direct-current stimulation (tDCS), Placebo
Device
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

NCT00216281
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine augmented with atomoxetine up to 40 mg or placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 10, 2026, 4:14 PM EDT